Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3892MR)

This product GTTS-WQ3892MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3892MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15913MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ15987MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ14351MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ5522MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ15778MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ8073MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ2985MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ2983MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW